Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Rhea-AI Summary

Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and CEO, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026 at 1:30pm ET. Registration is available via the conference website.

News Market Reaction – ANAB

-0.72%

3 alerts

-0.72% Session close to close

$2.03B Market Cap

0.2x Rel. Volume

In the May 5 session, ANAB declined 0.72%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights ANAB’s participation in a virtual royalty-focused conference, aligning ...

Analysis

This announcement highlights ANAB’s participation in a virtual royalty-focused conference, aligning with its repositioning as a manager of financial collaborations for Jemperli and imsidolimab. There are no new clinical or financial disclosures in this update. In context, the company recently completed a spin-off, executed capital actions, and saw pivotal imsidolimab data tied to a BLA with a December 12, 2026 action date. Investors may watch future royalty performance and regulatory milestones for more material catalysts.

Key Figures

Conference date: May 6, 2026 Fireside chat time: 1:30pm ET Conference edition: 2nd Annual

3 metrics

Conference date May 6, 2026 H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

Fireside chat time 1:30pm ET Scheduled start time for ANAB fireside chat

Conference edition 2nd Annual H.C. Wainwright Royalty Company Virtual Conference

Historical Context

5 past events · Latest: Apr 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Clinical/BLA update	Positive	-5.7%	NEJM Evidence publication and BLA status for imsidolimab in GPP.
Apr 24	Legal outcome	Positive	+14.8%	Court ruling in favor of Anaptys dismissing Tesaro anticipatory breach claim.
Apr 20	Spin-off completion	Positive	-24.5%	Completion of First Tracks spin-off and transition to royalty-focused model.
Mar 27	Private placement	Negative	-11.7%	First Tracks private placement funding clinical programs and spin-off launch.
Mar 27	Spin-off approval	Positive	-11.7%	Board approval of First Tracks spin-off and TRAX share distribution terms.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often produced sharp moves, with several positive strategic updates followed by negative price reactions.

Recent Company History

Over the last few months, ANAB has undergone significant strategic change, including the board-approved spin-off and eventual launch of First Tracks Biotherapeutics, plus a related private placement and capital return actions. Legal and clinical milestones include a favorable Delaware Chancery Court ruling and publication of pivotal Phase III imsidolimab data tied to a BLA with a December 12, 2026 FDA action date. Today’s conference-participation news follows this period of restructuring and clinical validation activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.

To register for the conference, please visit https://hcwevents.com/royalty-company-conference.

About Anaptys

Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Contact:
Anaptys Investor Relations
investors@anaptysbio.com

FAQ

When will Anaptys (ANAB) present at the H.C. Wainwright Royalty Company Virtual Conference?

Anaptys will present on May 6, 2026 at 1:30pm ET in a scheduled fireside chat. According to Anaptys, Daniel Faga, president and CEO, is the company representative speaking during the session.

Who from Anaptys (ANAB) will speak at the May 6, 2026 fireside chat?

Daniel Faga, president and CEO of Anaptys, will participate in the fireside chat. According to Anaptys, he will discuss the company’s collaborations and corporate overview at the virtual conference.

How can investors register for the H.C. Wainwright conference where ANAB will present?

Investors can register via the H.C. Wainwright conference registration page linked by the organizer. According to Anaptys, the virtual event sign-up is available on the conference website for attendees.

What topics will Anaptys (ANAB) likely cover in the May 6, 2026 fireside chat?

The fireside chat will likely focus on Anaptys’ financial collaborations and program updates. According to Anaptys, the company manages partnerships for Jemperli with GSK and imsidolimab with Vanda, which may be discussed.

Will the Anaptys (ANAB) fireside chat at H.C. Wainwright be available as a webcast or replay?

The announcement gives a scheduled start time but does not specify a replay or webcast details. According to Anaptys, attendees should check the conference website for access and any available recordings.